Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


AZ spreads good cancer news

Posted 9 June 2021 PM

AstraZeneca and MSD have released results pointing to a new early breast cancer indication for blockbuster PARP inhibitor Lynparza. 

Lynparza was PBS listed for use in ovarian, fallopian tube or primary peritoneal cancer after a Budget announcement in 2020 with Prime Minister Scott Morrison describing the listing as his "pet project".

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options